University of Pennsylvania in collaboration with Advaxis Inc. are working on an osteosarcoma vaccine for dogs. The aim is to prevent metastatic spread by employing the immune system to recognize and kill cancer cells that still remain in the body after limb amputation and thus increase the overall survival time.
The clinical trials are evaluating the safety and efficacy of a genetically modified bacteria-based vaccine.
Comparing their vaccinated dogs with a group of dogs with the same type of bone cancer and who received the same treatment, but were not vaccinated, the vaccine group is surviving significantly longer.
The vaccine appears to be safe with minimal side effects that resolve on their own.
They will also test using the vaccine for dogs that cannot undergo amputation. The goal is to determine whether combining the vaccine with palliative radiation therapy can eliminate pain, slow down the disease and increase overall survival.
Mason Osteosarcoma Vaccine Trial
Study: Evaluation of a recombinant bacteria vaccine to treat bone cancer in dogs
Advaxis Reports Encouraging Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma Study